All News

Results of the POETYK PsA-2 trial indicate deucravacitinib’s effectiveness at reducing the severity and burden of symptoms in patients with psoriatic arthritis.

Although improvements were observed in blood pressure (BP) medication adherence, there were no improvements in stain or glucose-lowering medication use.

Patients may have concerns about the boxed warning and other potential adverse effects associated with topical ruxolitinib for atopic dermatitis and vitiligo.

Though rare and typically presenting as transient, a case study demonstrates severe, chronic neutropenia in a patient with multifocal motor neuropathy treated with intravenous immunoglobulin (IVIG).

Wafa Samara, PharmD, vice president and chief pharmacy officer at City of Hope, highlights the vital role of oncology pharmacists at City of Hope in improving patient outcomes, conducting and leading research, and working as integral members of the multidisciplinary care team.

If approved, vutrisiran would be the first FDA-approved therapy to treat both the polyneuropathy and cardiomyopathy aspects of transthyretin amyloidosis (ATTR).

Icotrokinra, an oral pill that blocks the IL-23 receptor, had a favorable safety profile in adults and adolescents 12 years and older with moderate-to-severe plaque psoriasis.

Even when safe, oral supplement use may not be appropriate to use during cancer treatment or recovery.

COVID-19 changed the personal and professional lives of all pharmacy workforce members. But what now?

Long-acting injectables offer a promising approach to schizophrenia treatment, but their effective use requires careful management and patient education.

In older postmenopausal women, leukocyte count was found to be an independent predictor of long COVID symptom severity, highlighting its potential for use as a novel symptom biomarker.

Currently, EN001 is undergoing evaluation in a phase 1b trial.

AI can streamline biosimilar adoption by simplifying prescribing decisions and reducing costs.

Conference Co-Chair and American Association for Cancer Research (AACR) Past President Elaine R. Mardis, PhD, explains that the conference provides pharmacy professionals with insights into the application of large-scale cancer genomics studies to real-world therapeutic responses.

Amir Ali, PharmD, BCOP, discusses his experience as an oncology pharmacist in both direct and indirect patient care at the University of Southern California (USC) Norris Comprehensive Cancer Center.

The outbreak has grown to a total of 222 confirmed cases of measles, as well as 2 measles-associated deaths.

Pharmacists also navigate the REMS program and monitor and manage adverse effect profiles associated with bispecifics.

Sarcopenia, a progressive skeletal order that involves the accelerated loss of muscle mass and function, is associated with adverse outcomes such as functional decline, frailty, and mortality.

The novel formulation of trametinib has the potential to change the treatment paradigm of human papillomavirus (HPV) and prevent infections before they progress to deadly cancers.

The cancers linked with per- and polyfluoroalkyl substance (PFAS) exposure included nonastrocytoma gliomas, acute myeloid leukemia, and Wilms tumors.

Michael McGuire, PharmD, highlights the importance of early intervention in hospital settings, leveraging manufacturer programs, and navigating complex dosing regimens.

The treatment is currently undergoing evaluation in an investigational preclinical program and is projected to be in human trials in 2026.

A team of clinical and academic experts from the Association of Anaesthetists produced a consensus statement outlining the key components to minimizing the impact of harmful alcohol intake in the surgical population.

A pilot program integrated oncology pharmacists into prior authorization workflows to streamline and expedite medication approvals.

Subcutaneous infusion reduces treatment times for patients and eases operational burdens for providers.